Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.85 USD
Change Today +0.62 / 7.53%
Volume 59.6K
SCYX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

scynexis inc (SCYX) Snapshot

Open
$8.76
Previous Close
$8.23
Day High
$9.17
Day Low
$8.76
52 Week High
01/13/15 - $15.00
52 Week Low
08/7/14 - $5.10
Market Cap
123.0M
Average Volume 10 Days
31.9K
EPS TTM
$-2.39
Shares Outstanding
13.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SCYNEXIS INC (SCYX)

Related News

No related news articles were found.

scynexis inc (SCYX) Related Businessweek News

No Related Businessweek News Found

scynexis inc (SCYX) Details

SCYNEXIS, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, a novel oral drug that is in Phase II clinical trials; and an intravenous (IV) drug, which is conducting pre-clinical studies for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs that are approved for dry eye disease in humans and dogs. In addition, it provides contract research and development services in the field of animal health. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.

87 Employees
Last Reported Date: 03/30/15
Founded in 1999

scynexis inc (SCYX) Top Compensated Officers

President and Director
Total Annual Compensation: $533.2K
Chief Financial Officer
Total Annual Compensation: $332.1K
Compensation as of Fiscal Year 2014.

scynexis inc (SCYX) Key Developments

SCYNEXIS, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

SCYNEXIS, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $3,297,000 compared to $4,705,000 a year ago. Loss from operations was $6,385,000 compared to $1,781,000 a year ago. Net loss attributable to common stockholders - diluted was $6,384,000 compared to $1,221,000 a year ago. Net loss per common share, diluted was $0.75 compared to $6.57 a year ago. Net loss was $6,384,000 against net income of $412,000 for the same period a year ago. The net loss in the first quarter of 2015 was primarily due to costs associated with the development of SCY-078 and public company operating expenses. The net income for the first quarter of 2014 was primarily due to a gain of $2.8 million from a derivative fair value adjustment, largely offset by an operating loss of $1.8 million.

SCYNEXIS, Inc. Appoints David Angulo, M.D., as Chief Medical Officer, Effective June 1, 2015

SCYNEXIS, Inc. announced the appointment of David Angulo, M.D., as Chief Medical Officer, effective June 1, 2015. Dr. Angulo will be responsible for advancing the company's clinical development strategy and clinical operations for SCY-078, SCYNEXIS' lead clinical asset, currently in Phase 2 clinical development for the treatment of invasive fungal infections. Prior to joining SCYNEXIS, Dr. Angulo was Vice President, Research and Development with Brickell Biotech. Prior to that, he held various senior positions at Stiefel, a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infective area at Schering-Plough Corporation, and before that, he was an infectious disease physician in a pediatric hospital.

SCYNEXIS Explores To Sell Contract Research And Development Services Business

SCYNEXIS, Inc. (NasdaqGM:SCYX) is currently exploring a divestiture of contract research and development services business, and if it occurs it will cause us to incur substantial transaction costs and will cause a significant change in our business and financial performance in the future.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCYX:US $8.85 USD +0.62

SCYX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCYX.
View Industry Companies
 

Industry Analysis

SCYX

Industry Average

Valuation SCYX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.3x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCYNEXIS INC, please visit www.scynexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.